A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

Conditions

LB-P8 low-dose — DRUG
One capsule QD (1×10\^10 CFU/day) oral administration
LB-P8 high-dose — DRUG
One capsule QD (1×10\^11 CFU/day) oral administration
Placebo — DRUG
One capsule QD oral administration

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

Safety and tolerability of 2 different doses of LB-P8 [ Time Frame: (Part 1) Up to 4 weeks of treatment from the Baseline ]

Facility	City	State	ZIP	Site coordinators
University of California Davis	Sacramento	California	95817	University of California Davis 800-282-3284 Christopher Bowlus, MD (PRINCIPAL_INVESTIGATOR)
UCHealth University of Colorado Hospital	Aurora	Colorado	80045	UCHealth University of Colorado Hospital 7208480000 Lisa Forman, MD (PRINCIPAL_INVESTIGATOR)
University Of Iowa Hospitals And Clinics	Iowa City	Iowa	52242	University Of Iowa Hospitals And Clinics 319-356-1616 Alan Gunderson, MD (PRINCIPAL_INVESTIGATOR)
Mercy Medical Center	Baltimore	Maryland	21202	Mercy Medical Center 410-332-9000 Paul Thuluvath, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic	Rochester	Minnesota	55905	Mayo Clinic 507-284-2511 John Eton, MD (PRINCIPAL_INVESTIGATOR)
The Vanderbilt Clinic	Nashville	Tennessee	37232	The Vanderbilt Clinic 615-322-5000 Manhal Izzy, MD (PRINCIPAL_INVESTIGATOR)
Liver institute Northwest	Seattle	Washington	98105	Liver institute Northwest [email protected] 206-536-3030 Kris Kowdley, MD (PRINCIPAL_INVESTIGATOR)

By research site